Carnosine for Peripheral Arterial Disease Patients (Car-PAD)
Shahid Baba
Summary
Oral supplementation of L-carnosine will increase muscle carnosine, stabilize HIF1-alpha promote angiogenesis, and thus improve the functioning of lower extremities in PAD patients.
Description
Peripheral arterial disease (PAD) is caused by atherosclerotic occlusion of the lower extremities that reduces blood flow and leads to intermittent claudication and critical limb ischemia. PAD is diagnosed by calculating the ratio of blood pressure at the ankle to that of the arm (the ankle-brachial index \[ABI\]). An ABI of \<0.90 is indicative of atherosclerosis in the leg. Recent data from developed and developing countries have estimated that \>200 million people worldwide and approximately 12 million people in United States have PAD3. Both symptomatic and asymptomatic PAD patients have an…
Eligibility
- Age range
- 50–80 years
- Sex
- Male
- Healthy volunteers
- No
Inclusion Criteria: 1. Male subjects more than \>50 to \<80 years of age. 2. White or African American race. 3. English Speaking. 4. ABI 0.4-\< 0.60 5. Willing to comply with protocol requirements. 6. Able to provide informed consent. - Exclusion Criteria: 1. Subjects with HIV, hepatitis, significant liver disease, active infection, anemia, organ transplant, renal disease requiring dialysis, lung disease requiring oxygen, significant congenital heart disease, cancer of any type, and untreated thyroid disease. 2. Diagnosis of carnosinemia. 3. Known allergy to L-carnosine or meat. 4. Presence…
Interventions
- BiologicalCarnosine
Determine whether carnosine supplementation (2 g/day) for 3 months in peripheral arterial disease patients improves 6MWT ability.
Location
- University of LouisvilleLouisville, Kentucky